Cancer Treatment Reviews

Papers
(The TQCC of Cancer Treatment Reviews is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives196
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis186
Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines179
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review168
Systemic therapy for older patients with early breast cancer125
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in123
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group110
Editorial Board108
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis103
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer91
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas87
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer85
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)78
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer77
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials76
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty72
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches71
If it’s a target, it’s a pan-cancer target: Tissue is not the issue66
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis65
Editorial Board61
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features60
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.59
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?58
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis57
Emerging antibody-based therapies for the treatment of acute myeloid leukemia56
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies53
Uncertainties and controversies in axillary management of patients with breast cancer53
Optimizing care in early phase cancer trials: The role of palliative care53
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck52
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC51
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials50
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes50
Roadmap to cure multiple myeloma50
Editorial Board49
Editorial Board49
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment45
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges45
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?45
Blood biomarkers for differential diagnosis and early detection of pancreatic cancer44
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations44
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review43
Overview of BH3 mimetics in ovarian cancer41
Coordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination41
Editorial Board41
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis41
The immunogram of inflammatory breast cancer41
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design40
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier39
Extracellular vesicles and the “six Rs” in radiotherapy39
Editorial Board39
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review38
De-escalation of axillary irradiation for early breast cancer – Has the time come?38
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside38
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)37
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada37
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features37
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma37
Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis37
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities36
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives35
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer35
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma35
Agnostic drug development revisited34
Editorial Board34
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer33
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer33
Malignant ascites: Current therapy options and treatment prospects32
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies32
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review32
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)32
Bone complications of cancer treatment32
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review31
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers31
The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer31
Editorial Board31
Systematic review of the CUP trials characteristics and perspectives for next-generation studies31
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review30
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review30
Acknowledgement to Reviewers 202130
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?29
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?29
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis29
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications28
Cabozantinib: An evolving therapy for hepatocellular carcinoma28
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes27
Treatment landscape of metastatic pancreatic cancer27
Local control strategies for management of NSCLC with oligoprogressive disease27
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review26
Editorial Board26
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification26
Engineering strategies to optimise adoptive cell therapy in ovarian cancer25
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis25
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges25
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project24
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence24
Corrigendum to “Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis” [Cancer Treatm. Rev. 93 (2021) 102141]23
Review: Targeting EZH2 in neuroblastoma23
High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review23
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis23
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis22
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives22
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond22
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]21
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer21
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie21
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS – GROUP). Part I21
Strategies for improving detection of circulating tumor DNA using next generation sequencing20
Editorial Board20
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature20
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review20
Pharmacotherapy for leptomeningeal disease in breast cancer20
Evolving immunotherapeutic solutions for triple-negative breast carcinoma20
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications20
Diagnostics, therapeutics and RET inhibitor resistance for RET fusion–positive non-small cell lung cancers and future perspectives20
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives20
Editorial Board20
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases20
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment20
Considerations regarding a network meta-analysis of targeted therapies for BRAF-mutant unresectable or metastatic melanoma19
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives19
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis19
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review19
A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors19
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors19
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis19
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672]19
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies19
SELNET clinical practice guidelines for soft tissue sarcoma and GIST19
0.071556806564331